Sports journalist who grew up in Dallas, TX. Lover of all things sports, she got her degree from Texas Tech University (Wreck ‘em Tech!) in 2011. Joined Diario AS USA in 2021 and now covers mostly ...

If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock ...

Scottish sports journalist and content creator. After running his own soccer-related projects, in 2022 he joined Diario AS, where he mainly reports on the biggest news from around Europe’s leading ...

Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...

Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer. Under the terms of the deal, Exact Sciences' stockholders would receive $105 per share in cash. The ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Abbott Laboratories ABT0.97%increase; green up pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS-0.03%decrease; red down pointing triangle in a deal valued at about ...

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...